LipsitchM, SwerdlowDL, FinelliL. Defining the epidemiology of Covid-19-studies needed. N Engl J Med, 2020; 382:1194–1196.
2.
VaughtJ. Biobanking during the COVID-19 pandemic. Biopreserv Biobank, 2020; 18:153–154.
3.
BrankovićI, MalogajskiJ, MorréSA. Biobanking and translation of human genetics and genomics for infectious diseases. Appl Transl Genom, 2014; 3:30–35.
4.
MorelC, McClureL, EdwardsS, et al. (Eds.), Ensuring innovation in diagnostics for bacterial infection: Implications for policy [Internet]. European Observatory on Health Systems and Policies; 2016. (Observatory Studies Series, No. 44.) Available at: https://www.ncbi.nlm.nih.gov/books/NBK447319/ (last accessed April22, 2021).
5.
LajaunieC, HoCW-L. Pathogens collections, biobanks and related-data in a One Health legal and ethical perspective. Parasitology, 2018; 145:688–696.
6.
BartschSM, GorhamK, LeeBY. The cost of an Ebola case. Pathog Glob Health, 2015; 109:4–9.
7.
Morales-Suárez-VarelaM, Llopis-GonzálezA, González-CandelaF, et al.Dominguez, economic evaluation of health services costs during pandemic influenza A (H1N1) Pdm09 infection in pregnant and non-pregnant women in Spain. Iran J Public Health, 2016; 45:423–434.
8.
Gonzalez-SanchezMB, Lopez-ValeirasE, MorenteMM, Fernández LagoO. Cost model for biobanks. Biopreserv Biobank, 2013; 11:272–277.
9.
AlbertM, BartlettJ, JohnstonRN, SchacterB, WatsonP. Biobank bootstrapping: Is biobank sustainability possible through cost recovery?. Biopreserv Biobank, 2014; 12:374–380.
